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Abstract. Desriani, Budiarto BR, Harahap WA, Warisman MA, Ompusunggu AVC, Athariah D, Mirnawati F, Sriyani IY, Alahwani F,
Kurniawan AR. 2016. Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing
the trastuzumab predictive response diagnostic kit. Biodiversitas 17: 647-652. HER-2 overexpression is well known as a poor
prognostic factor for breast cancer patients. Targeted therapy can be carried out using monoclonal antibody named trastuzumab. Some
reports have higlighted the core problem of HER2 positive-breast cancer resitance on trastuzumab due to incorrect in selecting HER2
status patient who will reciept the drug and the emergence of PIK3CA mutations especially in exon 9 and 20 which is the downstream
of HER-2 pathway. In this study, data provision of PIK3CA gene and preparation of plasmid to support developing the trastuzumab
predictive response diagnostic kits will be reported. Based on direct DNA sequencing result, two samples of 68 breast cancer patients
exhibited mutation at exon 20 H1047R, while another three samples showed silent mutation (T1025T) at the same exon. On the other
hand, careful strategy should be considered for exon 9 analysis, since we found that almost 68 samples sequenced none of them were
exon 9 positive (pesudogene). Two prepared plasmids, pGEMT-easy PIK3CA exon 9 and 20 will be applied as control PIK3CA gene
for qPCR SYBR green I-based PIK3CA genotyping, while pGEMT easy HER-2 will be applied as a reference gene for scoring HER-2
status. The standard curve equation of plasmid-cloned HER2 gene amplification was Y=-3,0472x + 46,465, R2= 0,99 with qPCR
efficiency was 115%, respectively. Inconclusion, data provision and control DNA preparation of predicted factors for breast cancer
patients who positively respond to trastuzumab are very fundamental important aspects for the development of trastuzumab response
diagnostic kit which is based on Indonesian population genetics profile.
Keywords: Breast cancer, DNA, PIK3CA, HER-2, resistance trastuzumab, mutation
INTRODUCTION
Cancer is one of the leading causes of death worldwide.
In 2012, it was approximately 8.2 million deaths caused by
cancer. Lung cancer, liver, stomach, colorectal, and breast
cancer are the biggest cause of cancer deaths each year.
Cancer is regulated by many genes, known as oncogenes
which express oncoprotein. The emergence of oncogenes
could be as results of mutation, amplification and so forth.
Some of cancer diagnostic test have been developed not
only in the genomic level but also in the proteomic level as
well. Oncotype DX test is an example of detection
techniques in genomic level. Oncotype DX test has been
manufactured and commercialized. With this test, as many
as 21 cancer biomarker genes can be detected at the
genomic level. These targeted genes were determined
based on American Society of Clinical Oncology (ASCO)
and National Comprehensive Cancer Network (NCCN)’s
guideline and it has widely been applied by Oncologist in
therapying and treating their cancer patient. At the protein
level, oncoprotein detection in serum can be analyzed using
two-dimensional gel electrophoresis (2-DE). Examination
of information obtained can be used for the same purposes
as the Oncotype test (Wang et al. 2003)
Trastuzumab is a monoclonal antibody for targeted
therapy purposes in cancer patients with overexpressed
HER-2 status. HER-2 protein regulates the malignancy of
cancer through cell proliferation, angiogenesis, migration
and invasion. HER-2 and HER-3 interaction mainly effect
on metabolism process through PIK3CA pathway. This
Dimer formation may be a key determinant for sensitive of
breast cancer to HER-2 targeted therapy (Hynes and Dey
2009; Wang et al. 2011; Paplomata and O’Regan 2014).
Detailed molecular mechanisme of Trastuzumab
recognizes its target was unclear yet, but some evidence
highlighted the mechanism where this antibody does its
action on breast cancer such as (1) blocking of HER-2
dimerization that effected on the signal transduction
pathway, and (2) activation of antibody dependent cell
mediated cytotoxicity for tumor cell lysis. The duration of
trastuzumab therapy according to NCCN, St Gallent were
approximately 12 month duration of orally taken drug
therapy. Since the prize of the drug was expensive, it takes
careful consideration to decide whether the patients are true
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for the targeted drug in term of HER2 status. Some reports
have shown the high resistance incidence due to
trastuzumab treatment for non-target ones. False
interpretation of immunohistochemistry (IHC) results in
scoring of HER-2 status as the main factor for that incident.
Another factor is phophatidylinositol 3-kinases/ PIK3CA
gene mutation. In breast epithelial cells, this gene acts as a
regulator of the cellular growth, cell migration, survival,
apoptosis and proliferation. This gene located on HER-2
signaling pathway, encodes the p110α catalytic subunit of
the PI3K enzyme. These mutations cause the lipid kinase
activity increased two times higher, producing an increase
of phosphorylated AKT protein and hence inducing
oncogenic transformation. These mutations are generally
clustered in exon 9 and 20 of PIK3CA gene. Mutations in
PIK3CA are also found in other exons but in very rare
frequency. Patients harbor simultaneously mutations at
E545K and H1047R position have been reported to be
more resistant to therapy than other mutant types based on
in vitro study. ESMO at 2014 has officially issued that
detection of PIK3CA mutation in cancer patients is
required to predict their response to trastuzumab.
Furthermore, PIK3CA mutations have also been reported
as a potential biomarker for predicting prognostic status in
breast cancer patients. Indeed, PIK3CA mutations is
associated with increased tumor aggressiveness
(Kurebayashi et al. 2001; Gallia et al. 2006; Kato et al.
2007; Hale et al. 2008; Zhao et al. 2008). So far, targeted
therapy using trastuzumab given to breast cancer patient is
solely based on IHC result. The high percentage of
resistance to trastuzumab in single used reached over 60-
80%, indicating that HER-2 test which is only refer to IHC
alone is not enough. Moreover, IHC test is currently known
to be subjective due to the factors of operator skill and the
type of antibody used which potentially lead to misreading.
Based on this finding, the quantifying of HER-2 status
using other molecular methods with complement to existed
methods is significant to be developed (Clifford and Hudis
2007; Siddig et al. 2008; Breyer 2009; Cremoux et al.
2012; Alaoui-Jamali et al. 2015). In a diagnostic kit for
cancer detection, the standard reagent preparation was one
of the important things to be well prepared.
Here,  the development of trastuzumab predictive
response diagnostic kits through PIK3CA gene data
provision and plasmids preparation to support the
diagnostic kit study will be reported. We provided diversity
data of PIK3CA gene exon 9 and 20 detected with Sanger
DNA sequencing. We have also prepared three
recombinant plasmids as part of manufacture the predictive
factor detection kit at genomic level for patient
responsiveness against trastuzumab where two of them
were applied for PIK3CA genotyping in exon 9 and exon
20 while the other for HER-2 status scoring. The diversity
data in term of PIK3CA mutation obtained in this study and
the PIK3CA gene-contained recombinant plasmids can be
as a basis for creating and validating new cancer detection
kit which is unique only for PIK3CA genotypes originated
from Indonesian population. Furthermore, HER2-contained
recombinant plasmid can be applied as part of standard kit
preparation in qPCR to overcome the subjectivity problem
of IHC methods, avoiding false interpretation that may
occurs. The prepared control plasmids could significantly
contribute to the quality controls and quality assurance
program of cancer detection kit for predictive factors to
trastuzumab treatment.
MATERIALS AND METHODS
Genomic DNA isolation from Breast Cancer Tissue
The research was conducted using ethical clearance
issued by Indonesia Ministry of Health. Breast cancer
tissues were provided from several hospitals in West
Sumatra province, Indonesia. The fresh tissue samples
were stored at -80°C. Extraction was done using PureLink®
Lysate-Mini Kit from Invitrogen. The Genomic DNA
obtained then was confirmed using electrophoresis with 1.5
% agarose, visualized with UV-Transilluminator.
The PIK3CA gene amplification and sequencing
For HER-2 primer were forward Primer (5'-TGA TCT
GCC CAC AGA CTC-3 ') and reverse Primer (5'-TCT
CAT CGT CCG CTT GTA CC-3'), for PIK3CA exon 9 5’
AGT AAC AGA CTA GCT AGA GAC AAT 3’, reverse
primer 5’ CTG TGA CTC CAT AGA AAA TCT 3’, Primer for
PIK3CA gene exon 20 were (5’-TTT TTT CCT TCT CCA
TCA TTT CTA-3’, reverse primer (3’-GTT TCA GGA
GAT GTG TTA CAA-5’). PCR composition used are 12.5
µL of DreamTaq Green PCR Polymerase, 0.25 µL of
forward primer, 0.25 µL of reverse primer, 5.5 µL of
MilliQ nuclease-free water, and 0.25 µL of genomic DNA.
The PCR condition used as follows: pre-heat at 95°C for 5
minutes then followed by 35 cycle of denaturation at 95°C
for 30 seconds, annealing at 50.9°C for 30 seconds,
extension at 72°C for 30 seconds. After the PCR process
completed, the gene was confirmed using DNA
electrophoresis with 1.5% agarose, visualized with UV-
Transilluminator. Gene sequencing was done using
Applied Biosystem® 3100 Genetic Analyzer based on
Sanger method.
Purification, ligation, transformation
PCR product was purified using Wizard SV® Gel from
Promega, then was inserted to pGEM®-T Easy following
manufacture instruction. Transformation to E. coli DH5α
competent cells were done with heat shock method and
were spread in LB media containing with 100 ppm of
ampicillin, 50mM of X-Gal, and 1 mM of IPTG for
selecting targeted and non-targeted E. coli. Positive
bacteria colonies (containing recombinant plasmids) will be
white while the negative bacteria will be blue.
PCR colony for screening targeted E. coli
Suspected white colony of E. coli may contain targeted
gene were screened with colony PCR method. The
procedure was as follow: The white competent cell
colonies were taken slightly with sterile toothpicks and
used as a PCR template. Each tube is labeled in accordance
with the number of colonies in the Petri dish, than placed
into thermal cycler with PCR condition same as above PCR
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methods, except for HER-2 confirmation we used 5’-
CCAGCCCTCTGACGTCCAT-3’ for forward primer and
5’-CGTGTACTTCCGGATCTTCTGCTG-’3 for reverse
primer which recognized inside HER-2 producing 116 bp
PCR product. Positive clone than were cultured for
overnight in an incubator shaker at the speed of 150 rpm
and temperature 37°C.
Plasmid extraction
Plasmid extraction was done using High-Speed Plasmid
Mini Kit from Geneaid. The plasmid result then visualized
with UV-Transilluminator.
Control curve standardization for HER-2 amplification
pGEMT-easy HER-2 serial dilutions were started from
12.5 ng diluted by two times for each in five spots.
Dilutions were used as plasmid copy number standards to
generate a standard curve and to quantify her-2
chromosomal DNA copies. General formula used:  (6.02 x
1023 copies/mol) x (concentration in g/μL) / (MW in g/mol)
= copies/μL (Mendoza et al. 2013).
qPCR experimental conditions
For amplification and data collection we used CFX-96
Real-Time PCR from Biorad. Reactions were carried out in
triplicates, SYBR-Green from KappaBiosains®, 1µM of
each primer. Cycling conditions were 95˚C for 5 min, 35
cycles; at 95˚C for 30 sec; at 60˚C for 10 sec and at 72˚C
for 30 sec.
RESULTS AND DISCUSSION
PIK3CA data provision
There are many theories which trastuzumab resistance
problems arise. Some of report showed that mutation in
PIK3CA gene especially in the hotspot area such as in exon
9 and 20 contributed to the therapy implication. Patients
with mutation in this hotspots area have been shown
unresponsive toward trastuzumab therapy.
Based on sequencing method, two samples among 68
breast cancer samples obtained from West Sumatra
province of Indonesia showed mutation in exon 20 H1047R
(2.94%) and three samples showed T1025T silent mutation
(4.41%). While for exon 9 study careful strategy should be
considered, since we found almost 68 samples showed
mutation at A1634C (E545A) position and a base deletion
at nucleotide 1659 which referred as pseduogene (Samuel
et al. 2004). Mutation in exon 20 H1047R was reported to
have oncogenic capability and it was responsible for
trastuzumab resistance problems, while T1025T position
has no reports implicate to cancer development. Mutation
in PIK3CA gene quite varies around 8%-40% and the
contribution of this mutation to prognostic implication is
still controversial (Levine et al. 2005; Mangone et al. 2012;
Arsenic et al. 2014). According to Li et al. (2006), mutation
in exon 20 of PIK3CA gene were predominated in breast
cancer. To confirm the data obtained in this study, the large
number for PIK3CA study is needed for future works.
Although the percentage of mutations were low in
Indonesian breast cancer especially in West Sumatra
province, the detection system is important to be prepared
since H1047R has oncogenic capabilities. According to
Meyer et al. 2013, PIK3CA H1047R was able to induce
mammary tumor growth compared to its wild type and also
this mutant showed more oncogenic pontency compared
with PIK3CA E545K in the transgenic mouse models.
Furthermore, PIK3CA mutations was reported associated
with lower tumor stages which mean it could be as a
biomarker for early tumor detection (Rudd et al. 2011;
Dumont et al. 2012). Prepared recombinant plasmids and
the results of PIK3CA genotyping could be used for
developing and validating a new method for predictive
factor therapy with trastuzumab in genomic level in future.
Control DNA preparation for pGEM-T easy HER-2
and PIK3CA gene exons 9 and 20
HER2 gene as a predictive factor of treatment with
trastuzumab using was successfully cloned into pGEM-T
easy plasmid as a vector. This prepared plasmid was
required as a control to support targeted detection kit
development. Furthermore, the performance of the kit such
as sensitivity, specificity, reproducibility and suitability are
prerequisite to be performed before the kit commercially
produced. The property of the kit and all the associated
reagents should fulfill the sensitive, specificity, fast and
easy to interpret the result (Yang and Rothman 2004).
Table 1. Mutations profile in exon 20 of PIK3CA gene
Mutation Amino acid changesSample
code 1025 codon 1047 codon 1025 codon 1047 codon Mutation type
Mutation
nomenclature
0014 CAT
CGT
Histidin
Arginin
Substitution
 (Missense)
H1047R
0020 ACC
ACT
Threonin
Threonin
Substitution (Silent) T1025T
0022 ACC
ACT
Threonin
Threonin
Substitution (Silent) T1025T
0048 CAT
CGT
Histidin
Arginin
Substitution
 (Missense)
H1047R
0068 ACC
ACT
Threonin
Threonin
Substitution (Silent) T1047T
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Figure 1. Breast cancer genomic DNA (arrow)
Figure 2. PCR product for HER-2 (480 bp), PIK3CA exon 9 (124
bp) and exon 20 (619 bp). DNA ladder marker: 100 bp DNA
ladder (left) and 1Kb plus DNA ladder (right)
Figure 3. PCR colony of E.coli DH5α for HER-2 (116 bp),
PIK3CA exon 9 (124 bp) and exon 20 (619 bp). DNA ladder
marker: 1 Kb plus DNA ladder.
Genomic DNA was used as template for PCR
amplification of exon 9 and 20 of PIK3CA as well as HER-
2 gene. The genomic extraction result is shown in the
Figure 1. The amplification, insertion and transformation of
targeted genes for each were shown in Figure 2.
The results of the preparation of plasmid were
sequenced to confirm the targeted gene (data not shown).
Three recombinant plasmids prepared then were preserved
in E. coli DH5α bacterial strain as glycerol stocks for future
usage.
pGEM-T easy PIK3Ca exon 9 and 20
Mostly cancer biomarker detection method was based
on PCR methods, which were massive, high-trough put and
rapid (Kristensen and Hanse 2009). Prepared recombinant
plasmids could be used as reference gene in conducting
breast cancer genotyping in Indonesia based on PCR
methods. The commercial products currently developed
and commonly used are ARMS and probe technique. Both
of the technique provides a negative and positive control
reaction in the detection kit. By using a prepared plasmid
not only could be applied as control part of the kit, but also
could be used to test and to develop new techniques easier
and cheaper avoiding limited sample usage. Here below the
plasmid map of pGEMT easy PIK3CA for exon 9 and 20.
pGEM-T easy HER-2 for standard curve calculation in
scoring HER-2
post-qPCR data processing can seriously affect the
interpretation of the results. If there is no reference gene it
is needed the wisdom of researchers in executing the data
processing. The standard curve in real time PCR approach
may have advantages. The standard curve method
simplifies calculations and avoids practical and theoretical
problems. (Mendoza et al. 2013). pGEM-T easy HER-2
was successfully tested for a standard curve preparation for
HER-2 scoring application.
Figure 4. Map pGEM-T easy PIK3Ca exon 9 (left) and exon 20 (right)
619 bp
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Figure 5. Standard curve of HER-2 amplification calculation
In the figure showed above, the curve is used as
reference to calculate the copy number and to score the
over expression of HER-2 by comparing between breast
cancer and normal patients. The standard curve equation
was Y=-3.0472x + 46.465, R2= 0.99, the efficiency was
115%. This equation meets the requirements in qPCR
theory. Quantifying HER-2 satus using qPCR was expected
to minimize the subjectivity in selecting HER2 positive
candidate among patients tested. HER-2 quantification
detection kit is already commercialized, such as by Roche.
The kit provides specific primers, hybridization probes,
positive and negative control reaction (Beyser et al. 2001).
Since the probes frequently used for the DNA labeling
process hence it directly causes the kits price becoming
slightly expensive. In our future detection kit development,
the application of such probe is avoidable in order to
minimize the price so that the kit will be more affordable
especially for Indonesia market.
PIK3CA data provision and three recombinant plasmids
preparation in our study are important aspect as a part of
supporting in development of diagnostic kit of predicted
factor for patients which is responsive to trastuzumab at
genomic level based on Indonesian population. The
provided kit could be applied for determination of HER2
amplification status and PIK3CA genotyping that those are
becoming the major cause for resistance towards
trastuzumab. Furthermore, the availability of these kits is
expected helping the oncologist from inappropriate
treatment of trastuzumab administrated-patients.
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